Chorea, psychosis, acanthocytosis, and prolonged survival associated with ELAC2 mutations
Citation Manager Formats
Make Comment
See Comments

Biallelic mutations in the elaC ribonuclease Z 2 (ELAC2) gene cause a rare mitochondrial disease, the main features of which are hypertrophic cardiomyopathy, delayed psychomotor development, and usually death during childhood.1 Only 20 families have been reported with this syndrome.1,–,3 Neither movement disorders nor psychotic features have been described as part of the spectrum of ELAC2 mutations. We describe a patient with a complex hyperkinetic syndrome and acanthocytosis, harboring biallelic ELAC2 mutations.
Case description
An Assyrian 69-year-old woman born in Turkey was evaluated at our center for a slowly progressive Huntingtonian disorder. Family history was negative. The patient came to Sweden at age 33; she never went to school and learned only a few Swedish words, and could perform simple transactions. She had type 2 diabetes mellitus, bilateral sensorineural hearing loss requiring aids since age 58, and a follicular thyroid tumor, and is a silent carrier of α-thalassemia (table e-1; doi.org/10.5061/dryad.j6s420k).
At age 52 years, the patient developed short memory impairment and increasing difficulties managing activities of daily living. Four years later, she reported olfactory hallucinations and became obsessed with cleaning and doing laundry to remove the perceived foul smells. Perioral movements were documented during an emergency room visit at age 56 for psychiatric issues, and were noted by her family to have been present for many years, predating treatment with aripiprazole. The olfactory hallucinations became so severe that she tried to commit suicide by setting her apartment on fire at age 58. This resulted in admission to a psychiatric unit for a year and treatment with aripiprazole. At age 61, worsened gait, balance, and involuntary movements were evident. For the last 3 years, she has required a walker and reports numbness in her calves. She has lost weight, but there is no evidence of feeding dystonia or dysphagia. Recently, she has become fecally incontinent.
On examination, the patient had chorea in the feet and perioral area, dystonic posturing in the hands and reduced arm movements, a waddling gait, bradykinesia, apraxia, and atrophy of the hand muscles (video 1). A simplified psychometric evaluation demonstrated significant deficits in several domains (table e-2). EEG performed twice was normal; neurophysiologic studies revealed a sensorimotor demyelinating polyneuropathy and myopathy. Muscle biopsy revealed both cytochrome oxidase (COX)–negative and ragged-red fibers. Brain MRI demonstrated atrophy in the left perirolandic frontal and temporal cortex, while FDG-PET showed reduced bilateral hypometabolism in these regions and in the insular cortex, more pronounced on the left side (figures e-1 and e-2; doi.org/10.5061/dryad.j6s420k). An incidental aneurysm in the anterior communicating artery was found and treated conservatively; there was no evidence of brain calcifications on CT scans. Huntington disease (HD) and other HD phenocopies were ruled out (appendix; doi.org/10.5061/dryad.j6s420k). Acanthocytes were found on wet blood smears (figure e-3; doi.org/10.5061/dryad.j6s420k). Whole exome sequencing revealed compound heterozygous variants c.394G>A (p.Gly132Arg) and c.1040C>T (p.Ser347Phe) in the ELAC2 gene (figure e-4; doi.org/10.5061/dryad.j6s420k). ECG was normal but repeated echocardiography demonstrated stable mild ventricular septum hypertrophy without evidence of pump failure. Although we did not find any evidence of respiratory chain defect in the muscle biopsy, the patient's fibroblasts revealed accumulation of unprocessed mitochondrial transcripts but normal steady-state levels of mitochondrial mRNAs and tRNAs (figure 1, A and B). These fibroblasts showed severe growth impairment when using galactose as energy source (figure 1C). Treatment with coenzyme Q10 has been started and regular echocardiography is planned.
Video 1
The patient has mild chorea involving the lower face, trunk, and upper and lower limbs, which increases with activation. There is dystonic posturing of the fingers and arms, and a mild postural tremor of the right hand. There is bradykinesia and clumsiness of alternating movements of both upper and lower extremities, which has progressed between examinations (at ages 63 and 67 years). She has a waddling, wide-based, gait, which has progressed between the 2 recordings, and the right arm is held in an abducted, dystonic posture. Speech is mildly dysarthric.Download Supplementary Video 1 via http://dx.doi.org/10.1212/006320_Video_1
(A) Steady-state levels of mitochondrial mRNAs. 18S rRNA was used as loading control. Controls: C1 and C2, patient: ELAC2mut. (B) Steady-state levels of mitochondrial tRNA-tryptophane (mt-tW) and the nuclear-encoded tRNA-cysteine (cyto-tC) from control (C1, C2) and patient fibroblasts, grown for 14 days on galactose-containing medium. *Unprocessed mitochondrial transcript, arrow = tRNA. (C) Growth curves of control and patient fibroblasts grown on galactose. Experiments were performed in triplicates. Error bars indicate standard error.
Discussion
This case demonstrates that ELAC2 mutations are not exclusively confined to a lethal pediatric cardiomyopathy but can also be associated with symptoms and laboratory findings suggestive of a neuroacanthocytosis syndrome. Most patients with biallelic ELAC2 mutations reported to date have died during early infancy. In a Saudi cohort of 16 patients harboring the homozygous c.460T>C (p.Phe154Leu) mutation, the mean survival was 4 months.3 This dire prognosis makes the prolonged survival of our case remarkable. Apart from our patient, the oldest surviving patient is a 19-year-old patient with severe developmental delay and inability to walk.2 There was no dysmorphism or microcephaly, as have been reported with ELAC2 mutations.1,2 Accumulation of unprocessed mitochondrial transcripts and impaired fibroblast growth on galactose support pathogenicity for the ELAC2 variants we report. Other mitochondrial diseases associated with chorea include Leigh syndrome and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS),4,5 although these are typically associated with basal ganglia lesions on imaging. Our patient had myopathy, hearing loss, diabetes, and polyneuropathy, which are typical of mitochondrial disease. Even though perioral chorea antedated treatment with aripiprazole, it is not possible to rule out that bradykinesia, dystonic hand posturing, and chorea in the trunk and feet may be side effects of this treatment. The radiologic abnormalities (unilateral frontal and temporal atrophy) and bilateral hypometabolism in the operculum and insula are also new findings for ELAC2 mutations. Interestingly, injuries in the insula have been reported in association with olfactory hallucinations.6
The presence of acanthocytosis, in addition to myopathy, polyneuropathy, and chorea, suggests a neuroacanthocytosis syndrome (i.e., chorea–acanthocytosis and McLeod syndrome, which were excluded in this case); dilated, but not hypertrophic, cardiomyopathy is typical in McLeod syndrome.7 One case of MELAS has been reported to be associated with acanthocytosis.8 We propose that ELAC2 should be added to the list of potential causes of neuroacanthocytosis syndromes.
Author contributions
M. Paucar, A. Wredenberg, R.H. Walker, K. Lagerstedt-Robinson, J. Laffita, A. Wedell, P. Svenningsson: study concept, data collection, writing of the manuscript. M. Paucar: wrote the first draft. A. Wedell, A. Wredenberg, C. Freyer, A. Pajak, H. Stranneheim, and K. Lagerstedt-Robinson: performed the assessment of mitochondrial function and genetic analysis. I. Savitcheva: contributed imaging data. Å. Bergendal: performed the cognitive evaluation. R.H. Walker, A. Wredenberg, A. Wedell, C. Freyer, Å. Bergendal, I. Savitcheva, J. Laffita, P. Svenningsson: editing of the manuscript.
Study funding
M. Paucar's research was supported by the Stockholm County Council. A. Wedell's research is supported by the Swedish Research Council (2016-01082), the Stockholm County Council (20170022), and the Knut & Alice Wallenberg Foundation (KAW 2013.0026 and KAW 2014.0293). A. Wredenberg is a Ragnar Söderberg Fellow in Medicine (M77/13); her research is supported by the Swedish Research Council AW (2016-02179), Stockholm County Council, and Knut & Alice Wallenberg Foundation. P. Svenningsson is a Wallenberg Clinical Scholar; his research is supported by the Stockholm County Council (ALF).
Disclosure
The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.
Publication history
Previously published at bioRxiv doi: 10.1101/244848. Received by Neurology: Neuroimmunology & Neuroinflammation February 8, 2018. Accepted in final form July 19, 2018.
Acknowledgment
The authors thank the patient and her son for participation; Dr. H. Salim for referring the patient; Dr. Inger Nennesmo for the neuropathologic investigation; and Nicole Lesko for assistance with the genetic data.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was funded by the authors.
The Article Processing Charge was funded by Swedish Research Council.
- Received February 8, 2018.
- Accepted in final form July 19, 2018.
- Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- 1.↵
- 2.↵
- 3.↵
- 4.↵
- 5.↵
- Adam MP,
- Ardinger HH,
- Pagon RA, et al.
- Rahman S,
- Thorburn D
- 6.↵
- Beume LA,
- Klinger A,
- Reinhard M,
- Niesen WD
- 7.↵
- Adam MP,
- Ardinger HH,
- Pagon RA, et al.
- Jung HH,
- Danek A,
- Walker RH,
- Frey BM,
- Gassner C
- 8.↵
Letters: Rapid online correspondence
- Reader response: Chorea, psychosis, acanthocytosis, and prolonged survival associated with ELAC2 mutations
- Shakya Bhattacharjee, Neurologist, MRCP (UK), Specialist Registrar, Plymouth Hospital NHS Trust (UK)
Submitted September 22, 2018
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan
Related Articles
- No related articles found.